Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ; I-SPY2 Investigators.

NPJ Breast Cancer. 2019 Jan 2;5:2. doi: 10.1038/s41523-018-0096-0. eCollection 2019.

2.

Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.

Brunette LL, Mhawech-Fauceglia PY, Ji L, Skeate JG, Brand HE, Lawrenson K, Walia S, Chiriva-Internati M, Groshen S, Roman LD, Kast WM, Da Silva DM.

BMC Cancer. 2018 Oct 11;18(1):970. doi: 10.1186/s12885-018-4880-x.

3.

Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element.

Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD.

Surg Oncol. 2018 Sep;27(3):433-440. doi: 10.1016/j.suronc.2018.05.017. Epub 2018 May 11.

PMID:
30217299
4.

Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ; and I-SPY 2 Investigators.

NPJ Breast Cancer. 2018 Aug 17;4:26. doi: 10.1038/s41523-018-0074-6. eCollection 2018. Review. Erratum in: NPJ Breast Cancer. 2019 Jan 2;5:2.

5.

Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma.

Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Enomoto T, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD.

Ann Surg Oncol. 2018 Nov;25(12):3676-3684. doi: 10.1245/s10434-018-6695-z. Epub 2018 Aug 13.

PMID:
30105438
6.

Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma.

Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Enomoto T, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD.

Ann Surg Oncol. 2018 Sep;25(9):2756-2766. doi: 10.1245/s10434-018-6547-x. Epub 2018 Jul 3.

PMID:
29971677
7.

Overexpression of HOMER2 predicts better outcome in low-grade endometrioid endometrial adenocarcinoma.

Mhawech-Fauceglia P, Walia S, Yessaian A, Machida H, Matsuo K, Lawrenson K.

Pathology. 2018 Aug;50(5):499-503. doi: 10.1016/j.pathol.2018.03.004. Epub 2018 Jun 8.

PMID:
29891190
8.

The diagnosis of mucinous lesions in endometrial samplings by gynaecological pathologists: an analysis of diagnostic reproducibility.

Fadare O, Roma AA, Mhawech-Fauceglia P, Parkash V, Rabban JT.

Pathology. 2018 Apr;50(3):276-285. doi: 10.1016/j.pathol.2017.09.014. Epub 2018 Feb 8.

PMID:
29428179
9.

A Case Report of an Adenomatoid Tumor of the Uterus Mimicking an Endometrioid Adenocarcinoma on Endometrial Curetting: a Diagnostic Pitfall.

Mhawech-Fauceglia P, Samroa D.

Appl Immunohistochem Mol Morphol. 2018 Feb 5. doi: 10.1097/PAI.0000000000000614. [Epub ahead of print]

PMID:
29406333
10.

The PAX8 cistrome in epithelial ovarian cancer.

Adler EK, Corona RI, Lee JM, Rodriguez-Malave N, Mhawech-Fauceglia P, Sowter H, Hazelett DJ, Lawrenson K, Gayther SA.

Oncotarget. 2017 Nov 27;8(65):108316-108332. doi: 10.18632/oncotarget.22718. eCollection 2017 Dec 12.

11.

Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer.

Samanta S, Tamura S, Dubeau L, Mhawech-Fauceglia P, Miyagi Y, Kato H, Lieberman R, Buckanovich RJ, Lin YG, Neamati N.

Oncotarget. 2017 Oct 6;8(61):103543-103556. doi: 10.18632/oncotarget.21569. eCollection 2017 Nov 28.

12.

Metastatic Acinic Cell Carcinoma to the Vagina: A First Reported Case.

Hom M, Fong A, Sanford M, Mhawech-Fauceglia P.

Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):e39-e41. doi: 10.1097/PAI.0000000000000570.

PMID:
28800013
13.

Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.

Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond AM, Marcus JZ, Hilliard MAM, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Saglam O, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi R, Gabra H, Roman LD, Sood AK, Gershenson DM.

J Surg Oncol. 2018 Feb;117(2):236-244. doi: 10.1002/jso.24801. Epub 2017 Aug 8.

14.

High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.

Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF.

Gynecol Oncol. 2017 Jul;146(1):153-160. doi: 10.1016/j.ygyno.2017.04.012. Epub 2017 Apr 26.

15.

Endometrioid Adenocarcinoma Arising in a Paratubal Cyst: A Case Report and Review of the Literature.

Chang C, Matsuo K, Mhawech-Fauceglia P.

Appl Immunohistochem Mol Morphol. 2017 Mar;25(3):e21-e24. doi: 10.1097/PAI.0000000000000379. Review.

PMID:
28277338
16.

Endoplasmic reticulum stress in complex atypical hyperplasia as a possible predictor of occult carcinoma and progestin response.

Tierney KE, Ji L, Dralla SS, Yoo E, Yessaian A, Pham HQ, Roman L, Sposto R, Mhawech-Fauceglia P, Lin YG.

Gynecol Oncol. 2016 Dec;143(3):650-654. doi: 10.1016/j.ygyno.2016.10.015. Epub 2016 Oct 19.

PMID:
27771165
17.

Targeting Src in endometriosis-associated ovarian cancer.

Manek R, Pakzamir E, Mhawech-Fauceglia P, Pejovic T, Sowter H, Gayther SA, Lawrenson K.

Oncogenesis. 2016 Aug 15;5(8):e251. doi: 10.1038/oncsis.2016.54.

18.

Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.

Matsuo K, Takazawa Y, Ross MS, Elishaev E, Podzielinski I, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Matsuzaki S, Baba T, Satoh S, Shida M, Nishikawa T, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Fujiwara K, Hazama Y, Kadogami D, Moffitt MN, Takeuchi S, Nishimura M, Iwasaki K, Ushioda N, Johnson MS, Yoshida M, Hakam A, Li SW, Richmond AM, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Yamaguchi K, Oishi T, Kajiwara H, Hasegawa K, Yasuda M, Kawana K, Suda K, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Wakatsuki A, Sugiyama T, Pejovic T, Nagano T, Shimoya K, Andoh M, Shiki Y, Enomoto T, Sasaki T, Fujiwara K, Mikami M, Shimada M, Konishi I, Kimura T, Post MD, Shahzad MM, Im DD, Yoshida H, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD.

Ann Oncol. 2016 Jul;27(7):1257-66. doi: 10.1093/annonc/mdw161. Epub 2016 Apr 6.

PMID:
27052653
19.

RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer.

Chimge NO, Little GH, Baniwal SK, Adisetiyo H, Xie Y, Zhang T, O'Laughlin A, Liu ZY, Ulrich P, Martin A, Mhawech-Fauceglia P, Ellis MJ, Tripathy D, Groshen S, Liang C, Li Z, Schones DE, Frenkel B.

Nat Commun. 2016 Feb 26;7:10751. doi: 10.1038/ncomms10751.

20.

Nestin: A biomarker of aggressive uterine cancers.

Hope ER, Mhawech-Fauceglia P, Pejovic T, Zahn CM, Wang G, Conrads TP, Larry Maxwell G, Hamilton CA, Darcy KM, Syed V.

Gynecol Oncol. 2016 Mar;140(3):503-11. doi: 10.1016/j.ygyno.2015.12.015. Epub 2015 Dec 21.

PMID:
26718725
21.

Microfocus of Anaplastic Carcinoma Arising in Mural Nodule of Ovarian Mucinous Borderline Tumor With Very Rapid and Fatal Outcome.

Mhawech-Fauceglia P, Ramzan A, Walia S, Pham HQ, Yessaian A.

Int J Gynecol Pathol. 2016 Jul;35(4):348-51. doi: 10.1097/PGP.0000000000000252.

PMID:
26598983
22.

Characteristics of ovarian tumors of low malignant potential in BRCA mutation carriers: A case series.

Matsuo K, Tierney KE, Schneider DM, Mhawech-Fauceglia P, Roman LD, Gershenson DM.

Gynecol Oncol Rep. 2015 Jun 11;13:36-9. doi: 10.1016/j.gore.2015.06.003. eCollection 2015 Aug.

23.

Endometrioid adenocarcinoma associated with endometrial stromal sarcoma: A rare, often unrecognized collision tumor.

Kim G, Pham HQ, Ramzan A, Elishaev E, Mhawech-Fauceglia P.

Gynecol Oncol Rep. 2015 May 1;13:8-12. doi: 10.1016/j.gore.2015.04.005. eCollection 2015 Aug.

24.

Prediction of concurrent endometrial carcinoma in women with endometrial hyperplasia.

Matsuo K, Ramzan AA, Gualtieri MR, Mhawech-Fauceglia P, Machida H, Moeini A, Dancz CE, Ueda Y, Roman LD.

Gynecol Oncol. 2015 Nov;139(2):261-7. doi: 10.1016/j.ygyno.2015.07.108. Epub 2015 Aug 1.

PMID:
26238457
25.

Molecular Analysis of Mixed Endometrioid and Serous Adenocarcinoma of the Endometrium.

Lawrenson K, Pakzamir E, Liu B, Lee JM, Delgado MK, Duncan K, Gayther SA, Liu S, Roman L, Mhawech-Fauceglia P.

PLoS One. 2015 Jul 1;10(7):e0130909. doi: 10.1371/journal.pone.0130909. eCollection 2015.

26.

DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.

Zhang W, Barger CJ, Link PA, Mhawech-Fauceglia P, Miller A, Akers SN, Odunsi K, Karpf AR.

Epigenetics. 2015;10(8):736-48. doi: 10.1080/15592294.2015.1062206.

27.

PAX8 expression in ovarian surface epithelial cells.

Adler E, Mhawech-Fauceglia P, Gayther SA, Lawrenson K.

Hum Pathol. 2015 Jul;46(7):948-56. doi: 10.1016/j.humpath.2015.03.017. Epub 2015 Apr 15.

28.

Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something new.

Hwang H, Matsuo K, Duncan K, Pakzamir E, Pham HQ, Correa A, Fedenko A, Mhawech-Fauceglia P.

J Clin Pathol. 2015 Sep;68(9):710-7. doi: 10.1136/jclinpath-2015-202915. Epub 2015 May 19.

PMID:
25991737
29.

MOLECULAR FINGERPRINTS OF MIXED ENDOMETRIOID AND SEROUS ADENOCARCINOMA OF THE ENDOMETRIUM: IGCS-0044 Uterine Cancer, including Sarcoma.

Mhawech-Fauceglia P.

Int J Gynecol Cancer. 2015 May;25 Suppl 1:68. No abstract available.

PMID:
25955944
30.

Targeting the glucose-regulated protein-78 abrogates Pten-null driven AKT activation and endometrioid tumorigenesis.

Lin YG, Shen J, Yoo E, Liu R, Yen HY, Mehta A, Rajaei A, Yang W, Mhawech-Fauceglia P, DeMayo FJ, Lydon J, Gill P, Lee AS.

Oncogene. 2015 Oct;34(43):5418-26. doi: 10.1038/onc.2015.4. Epub 2015 Feb 16.

31.

Stromal Expression of Fibroblast Activation Protein Alpha (FAP) Predicts Platinum Resistance and Shorter Recurrence in patients with Epithelial Ovarian Cancer.

Mhawech-Fauceglia P, Yan L, Sharifian M, Ren X, Liu S, Kim G, Gayther SA, Pejovic T, Lawrenson K.

Cancer Microenviron. 2015 Apr;8(1):23-31. doi: 10.1007/s12307-014-0153-7. Epub 2014 Oct 21.

32.

Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three-dimensional genetic models of ovarian carcinogenesis.

Lawrenson K, Mhawech-Fauceglia P, Worthington J, Spindler TJ, O'Brien D, Lee JM, Spain G, Sharifian M, Wang G, Darcy KM, Pejovic T, Sowter H, Timms JF, Gayther SA.

Int J Cancer. 2015 Oct 15;137(8):1806-17. doi: 10.1002/ijc.29197. Epub 2015 Jul 2.

33.

Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer.

Daudi S, Eng KH, Mhawech-Fauceglia P, Morrison C, Miliotto A, Beck A, Matsuzaki J, Tsuji T, Groman A, Gnjatic S, Spagnoli G, Lele S, Odunsi K.

PLoS One. 2014 Aug 7;9(8):e104099. doi: 10.1371/journal.pone.0104099. eCollection 2014.

34.

NPPB is a novel candidate biomarker expressed by cancer-associated fibroblasts in epithelial ovarian cancer.

Lawrenson K, Grun B, Lee N, Mhawech-Fauceglia P, Kan J, Swenson S, Lin YG, Pejovic T, Millstein J, Gayther SA.

Int J Cancer. 2015 Mar 15;136(6):1390-401. doi: 10.1002/ijc.29092. Epub 2014 Aug 14.

35.

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.

Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, Zhang W, Akers SN, Griffiths EA, Miliotto A, Beck A, Batt CA, Ritter G, Lele S, Gnjatic S, Karpf AR.

Cancer Immunol Res. 2014 Jan;2(1):37-49. doi: 10.1158/2326-6066.CIR-13-0126.

36.

Expression of DNA repair proteins in endometrial cancer predicts disease outcome.

Mhawech-Fauceglia P, Wang D, Kim G, Sharifian M, Chen X, Liu Q, Lin YG, Liu S, Pejovic T.

Gynecol Oncol. 2014 Mar;132(3):593-8. doi: 10.1016/j.ygyno.2014.02.002. Epub 2014 Feb 6.

PMID:
24508840
37.

Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism.

Liao J, Qian F, Tchabo N, Mhawech-Fauceglia P, Beck A, Qian Z, Wang X, Huss WJ, Lele SB, Morrison CD, Odunsi K.

PLoS One. 2014 Jan 7;9(1):e84941. doi: 10.1371/journal.pone.0084941. eCollection 2014.

38.

Lower extremity pain as initial presentation of cervical cancer.

Dandapani SV, Mhawech-Fauceglia P, Palmer S, Senikowich M, Lin YG.

Gynecol Oncol Case Rep. 2013 Feb 21;5:13-5. doi: 10.1016/j.gynor.2013.02.004. eCollection 2013. No abstract available.

39.

Metastatic ovarian papillary serous carcinoma to the breast: Diagnosis and pitfalls.

Mhawech-Fauceglia P, Kay B, Li CJ, Lin YG.

Gynecol Oncol Case Rep. 2013 Jan 4;4:35-7. doi: 10.1016/j.gynor.2012.12.008. eCollection 2013.

40.

Recurrent leiomyosarcoma presenting as malignant arterial tumor thrombus.

Tierney KE, Rogers A, Mhawech-Fauceglia P, Lin YG.

Gynecol Oncol Case Rep. 2013 Jan 5;4:32-4. doi: 10.1016/j.gynor.2012.12.011. eCollection 2013.

41.

Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy.

Mhawech-Fauceglia P, Wang D, Samrao D, Kim G, Lawrenson K, Meneses T, Liu S, Yessaian A, Pejovic T.

Cancer Microenviron. 2014 Aug;7(1-2):33-9. doi: 10.1007/s12307-013-0140-4. Epub 2013 Nov 10.

42.

Developmentally restricted differentiation antigens are targets for immunotherapy in epithelial ovarian carcinoma.

Godoy H, Mhawech-Fauceglia P, Beck A, Miliotto A, Miller A, Lele S, Odunsi K.

Int J Gynecol Pathol. 2013 Nov;32(6):536-40. doi: 10.1097/PGP.0b013e318275a550.

43.

Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma.

Mhawech-Fauceglia P, Wang D, Samrao D, Liu S, DuPont NC, Pejovic T.

Gynecol Oncol. 2013 Jul;130(1):174-80. doi: 10.1016/j.ygyno.2013.03.030. Epub 2013 Apr 8.

PMID:
23578537
44.

ER+ /PR+ /TFF3+ /IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases.

Mhawech-Fauceglia P, Yan L, Liu S, Pejovic T.

Histopathology. 2013 Jun;62(7):976-85. doi: 10.1111/his.12096. Epub 2013 Apr 9.

PMID:
23570281
45.

A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro.

Lee JM, Mhawech-Fauceglia P, Lee N, Parsanian LC, Lin YG, Gayther SA, Lawrenson K.

Lab Invest. 2013 May;93(5):528-42. doi: 10.1038/labinvest.2013.41. Epub 2013 Mar 4.

46.

Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy.

Samrao D, Wang D, Ough F, Lin YG, Liu S, Menesses T, Yessaian A, Turner N, Pejovic T, Mhawech-Fauceglia P.

Transl Oncol. 2012 Dec;5(6):469-74. Epub 2012 Dec 1.

47.

Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients.

Mhawech-Fauceglia P, Wang D, Ali L, Lele S, Huba MA, Liu S, Odunsi K.

Cancer Immun. 2013;13:1. Epub 2013 Jan 15.

48.

MET/HGF Signaling Pathway in Ovarian Carcinoma: Clinical Implications and Future Direction.

Mhawech-Fauceglia P, Afkhami M, Pejovic T.

Patholog Res Int. 2012;2012:960327. doi: 10.1155/2012/960327. Epub 2012 Dec 25.

49.

AKT inhibition mitigates GRP78 (glucose-regulated protein) expression and contribution to chemoresistance in endometrial cancers.

Gray MJ, Mhawech-Fauceglia P, Yoo E, Yang W, Wu E, Lee AS, Lin YG.

Int J Cancer. 2013 Jul;133(1):21-30. doi: 10.1002/ijc.27994. Epub 2013 Feb 8.

50.

Elevated expression of the serine-arginine protein kinase 1 gene in ovarian cancer and its role in Cisplatin cytotoxicity in vitro.

Odunsi K, Mhawech-Fauceglia P, Andrews C, Beck A, Amuwo O, Lele S, Black JD, Huang RY.

PLoS One. 2012;7(12):e51030. doi: 10.1371/journal.pone.0051030. Epub 2012 Dec 7.

Supplemental Content

Loading ...
Support Center